Novo Nordisk A/S Aktie (A3EU6F) - Kurs Nasdaq Copenhagen - MarketScreener (2024)

FAQs

Is NVO a good stock to buy today? ›

Novo Nordisk has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings. The average price target for Novo Nordisk is $149.60.

According to our Novo Nordisk A/S stock prediction for 2025, NVO stock will be priced at $ 162.87 in 2025. This forecast is based on the stock's average growth over the past 10 years.

Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Its main product is the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy.

Novo Nordisk stock price stood at $143.30

According to the latest long-term forecast, Novo Nordisk price will hit $150 by the middle of 2024 and then $200 by the end of 2025. Novo Nordisk will rise to $250 within the year of 2027, $300 in 2029, $350 in 2031 and $400 in 2034.

At the moment, analysts expect NovoNordisk to deliver many years of strong earnings per share (EPS) and cash flow growth. Over the next three years, EPS is expected to grow at a compound average rate of nearly 23 per cent with continued strong growth thereafter.

Based on short-term price targets offered by five analysts, the average price target for Novo Nordisk comes to $153.60. The forecasts range from a low of $143.00 to a high of $163.00. The average price target represents an increase of 7.22% from the last closing price of $143.26.

For the year, Novo Nordisk expects sales to climb 19% to 27% in constant currency. The company also called for a 22% to 30% jump in operating profit. Novo Nordisk stock currently ranks No. 21 on the IBD 50 list of elite growth stocks.

The company is behind the blockbuster drugs Ozempic and Wegovy, which tackle diabetes and obesity, respectively. Surging sales of the drugs saw Novo Nordisk's profits rise by half last year, and potentially by a further quarter in 2024.

The severe effects Yazeed faced aren't common, but people's experiences taking Ozempic and its sister drug, Wegovy, can vary widely — from substantial weight loss and minimal discomfort on one end of the spectrum to extreme effects on the other.

Mounjaro

Mounjaro (tirzepatide) is a newer once-weekly injection for Type 2 diabetes. It works on the same targets in the body as Ozempic, plus an additional target. This results in greater A1C reduction and weight loss compared to Ozempic.

Why did they stop making Ozempic? ›

Why the Ozempic shortage happened. The worldwide shortage of semaglutide started to affect Australia in early 2022 when Novo Nordisk couldn't supply enough Ozempic to meet an unexpected increase in demand due to off-label prescribing for weight loss.

The 26 analysts offering 12 month price targets for Novo Nordisk A/S have a median target of 990.00, with a high estimate of 1,100.00 and a low estimate of 530.00. The median estimate represents a 0.16% increase from the last price of 988.40.

Novo Nordisk raised its outlook for 2024, nudging its sales growth outlook range one percentage point higher, to 19% to 27% at constant exchange rates. It also upped its operating growth forecast to 22% to 30% from a previous forecast of 21% to 29%.

Danish drug manufacturer Novo Nordisk's top product Ozempic - a glucagon-like peptide 1 - generated some 96 billion kroner in sales in 2023. Another GLP-1 product, Victoza, was the company's third best-selling product.

What are the analyst and broker recommendations for Novo Resources? The overall consensus recommendation for Novo Resources is Hold.

Taiwan Semiconductor Manufacturing has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings. What is Taiwan Semiconductor Manufacturing's price target? The average price target for Taiwan Semiconductor Manufacturing is $168.11.

ACADIA Pharmaceuticals's analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

A trillion-dollar stock by 2029

Eli Lilly's market capitalization currently tops $715 billion. The company needs a compound annual growth rate of about 7% to reach the coveted trillion-dollar mark in five years. That should be easy for the biotech considering the strength of its underlying business.